Metabolic syndrome in PCOS patients.
Conditions
Interventions
Intervention 1: Intervention group: Treatment by garlic tab 500 mg. Intervention 2: Control group: treatment by placebo of garlic tab.
Sponsors
Tarbiat modares University
Eligibility
Sex/Gender
Female
Age
15 Years to 49 Years
Inclusion criteria
Inclusion criteria: People are willing to participate in the study fertility age between 15-49 years Iranian women no pregnancy have at least literacy for read and write no Mellitus Diabets according to primary FBS no chronic and coagulation disorders lack of consumption Anti lipids and Anti hypertensive and anti coagulative drugs no consuming garlic in a daily diet more than one cubit
Exclusion criteria
Exclusion criteria: People with drug side effects.Individuals unwilling to continue to participate in the study failure to comply with treatment protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of Triglyceride. Timepoint: First of study and 8 weeks after intervention. Method of measurement: blood biochemistry test.;Level of cholesterol. Timepoint: First of study and 8 weeks after intervention. Method of measurement: blood biochemistry test.;Blood level of HDL. Timepoint: First of study and 8 weeks after intervention. Method of measurement: blood biochemistry test.;Blood level of FBS. Timepoint: First of study and 8 weeks after intervention. Method of measurement: blood biochemistry test.;Level of systolic and diastolic blood pressure. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Use of mercury barometer.;Waist to hip ratio. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Use of meter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of CRP. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Blood biochemistry test.;Menstrual dysfunction such as: Oligomenorrhea and amenorrhea. Timepoint: First of study and 8 weeks after intervention. Method of measurement: patient statements.;Clinical hyperandrogenemia. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Blood biochemistry test and clinical symptom.;Ultrasound view of the ovaries. Timepoint: First of study and 8 weeks after intervention. Method of measurement: Use of ultrasound.;Sexual function. Timepoint: First of study and 8 weeks after intervention. Method of measurement: FSFI questionnaire.;Quality Of life. Timepoint: First of study and 8 weeks after intervention. Method of measurement: MPCOSQ questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahideh Jahanian Sadatmahalleh
Tarbiat modares University
Outcome results
None listed